HLA-DQ polymorphisms with HBV infection: Different outcomes upon infection and prognosis to lamivudine therapy

Journal of Viral Hepatitis

Volumn 21, Issue 7, 2014, Pages 491-498

  Zhang, X ^a   Jia, J ^a   Dong, J ^b   Yu, F ^a   Ma, N ^a   Li, M ^a   Liu, X ^a   Liu, W ^a   Li, T ^a   Liu, D ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HBV infection; HLA DQ; lamivudine; polymorphisms

Indexed keywords

LAMIVUDINE; HLA DQ ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; CODOMINANCE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HAN CHINESE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VIRAL CLEARANCE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; HEPATITIS B, CHRONIC; MASS SPECTROMETRY; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GENOTYPING TECHNIQUES; HEPATITIS B, CHRONIC; HLA-DQ ANTIGENS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 84902214182     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12159     Document Type: Article

References (24)

1. Ocama P, Opio CK, Lee WM,. Hepatitis B virus infection: current status. Am J Med 2005; 118 (12): 1413.
2. Ott JJ, Stevens GA, Groeger J, et al,. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30 (12): 2212-2219.
3. Custer B, Sullivan SD, Hazlet TK, et al,. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (10 Suppl. 3): S158-S168.
4. Godkin A, Davenport M, Hill AV,. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 2005; 41 (6): 1383-1390.
5. Ben-Ari Z, Mor E, Papo O, et al,. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003; 98 (1): 144-150.
6. Zheng MH, Xiao DD, Lin XF, et al,. The tumour necrosis factor-alpha-238A allele increases the risk of chronic HBV infection in European populations. J Viral Hepat 2012; 19 (2): e11-e17.
7. Deng G, Zhou G, Zhai Y, et al,. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology 2004; 40 (2): 318-326.
8. Kim YJ, Kim HY, Kim JS, et al,. Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Viral Hepat 2010; 17 (7): 518-526.
9. Deng G, Zhou G, Zhang R, et al,. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008; 134 (3): 716-726.
10. Mbarek H, Ochi H, Urabe Y, et al,. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet 2011; 20 (19): 3884-3892.
11. Kumar V, Kato N, Urabe Y, et al,. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43 (5): 455-458.
12. El-Serag HB, Marrero JA, Rudolph L, et al,. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134 (6): 1752-1763.
13. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5): 1208-1236.
14. Kwak MS, Choi JW, Lee JS, et al,. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. J Viral Hepat 2011; 18 (10): e432-e438.
15. Rapti I, Dimou E, Mitsoula P, et al,. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45 (2): 307-313.
16. Singh R, Kaul R, Kaul A, et al,. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13 (12): 1770-1787.
17. Thursz M,. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001; 52 (2): 113-116.
18. Wang FS,. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 2003; 9 (4): 641-644.
19. Duan ZP, Zhao XY, Huang DZ, et al,. RANTES gene single nucleotide polymorphisms and expression in patients with chronic hepatitis B virus infection. Chin Med J (Engl) 2005; 118 (11): 909-914.
20. He Y, Zhao Y, Zhang S, et al,. Not polymorphism but methylation of class II transactivator gene promoter IV associated with persistent HBV infection. J Clin Virol 2006; 37 (4): 282-286.
21. An P, Winkler C, Guan L, et al,. A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis 2011; 203 (7): 943-947.
22. Zhang M, Zhou J, Zhao T, et al,. Dissection of a circulating and intrahepatic CD4(+)Foxp3(+) T-cell subpopulation in chronic hepatitis B virus (HBV) infection: a highly informative strategy for distinguishing chronic HBV infection states. J Infect Dis 2012; 205 (7): 1111-1120.
23. Thursz MR, Thomas HC, Greenwood BM, et al,. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997; 17 (1): 11-12.
24. Zinkernagel RM,. Immunology taught by viruses. Science 1996; 271 (5246): 173-178.